Lonza to Invest in Mid-Scale Biologics, Cell Therapy Manufacturing

Article

Lonza announces addition of mid-scale biologics manufacturing capacity and cell-therapy suites at Portsmouth, NH site.

Lonza Pharma & Biotech announced plans to add mid-scale mammalian capacity and cell-therapy suites at the company’s Portsmouth, NH facility. The investment was announced in a press statement on May 4, 2018.

The company plans to install multiple 6000-L bioreactors with construction expected to start in late 2018. The hybrid facility will feature full-suite process analytic technology, multi-variate analysis, and single-use technologies in an existing building.

Lonza also announced the installation of multiple cell-therapy suites at the Portsmouth site. In February 2018, the company identified Portsmouth as a clinical and commercial manufacturing center for cell therapies, providing customers access to facilities for Phase I through to commercial manufacturing in one location. The facility is expected to be operational by late 2018.

Source: Lonza Pharma & Biotech

 

Recent Videos
Simon Wright from Almac Pharma Services chats about shifting demand for commercial manufacturing services and how service providers are adapting to meet demand.
Ian Lafferty from Upperton discusses the trends and challenges facing sterile manufacturing and how partnering with CDMOs can help innovators progress to the market.
Related Content
© 2025 MJH Life Sciences

All rights reserved.